Henlius has pro-actively built a diversified and high-quality product pipeline covering over 20 innovative monoclonal antibodies (mAbs) and has continued to explore immuno-oncology combination therapies with proprietary HLX10 (anti-PD-1 mAb) as backbone. Up to date, the Company has successfully marketed 3 innovative monoclonal antibodies (mAbs), including 汉利康Ⓡ (rituximab), the first China-developed biosimilar, 汉曲优^® (trastuzumab, Zercepac in the EU), the first China-developed mAb biosimilar approved both in China and in the EU, and 汉达远^® (adalimumab), the first autoimmune disease treatment product developed by the Company. In addition, the NDA of HLX04 bevacizumab and HLX01 rituximab for new indications of rheumatoid arthritis is under review. Henlius has also concurrently carried out more than 20 clinical trials on 10 products and 8 combination regimens worldwide. The external authorization of the products fully covers the mainstream biopharmaceutical markets in Europe and the United States, as well as many emerging countries.